Natalizumab (Tysabri) Provides Superior ‘Feel Good’ Experience in MS Over Other Treatments

Stuart SchlossmanMS Research Study and Reports, Multiple Sclerosis, Tysabri

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
COVID-19 is unprecedented and rapidly changing situation.
Get public health information from CDC: https://www.coronavirus.gov 

Stay Healthy, Stay Home and Wash Your Hands
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

By: Marco Meglio  – Neurology LIVE

Published: May 27, 2020

Increases in physical, emotional, and cognitive functioning were more common in patients receiving natalizumab than in patients receiving other disease modifying therapies

Data from a patient-centric survey study presented at the 2020 Annual Meeting of the  Consortium of Multiple Sclerosis Centers (CMSC) suggests that treatment with natalizumab (Tysabri; Biogen) is associated with a greater “feel-good” experience compared with other disease modifying therapies (DMTs) for patients with relapsing-remitting multiple sclerosis (RRMS).1
John Foley, MD
          John Foley, MD

Click HERE to Subscribe for the MS Beacon Newsletter


Research conducted by John Foley, MD, neurology specialist, Rocky Mountain MS Clinic, and colleagues showed a significantly higher percentage of natalizumab patients “felt good” while on natalizumab (n = 95; 63%) compared with other DMT-treated patients (45%; n = 252; P = .001).

In total, 78% of natalizumab-treated patients self-reported physical benefits compared with 67% of other-DMT patients (P = .017). Additionally, significantly higher rates of improved energy (23% vs 12%; P = .011) and coordination (22% vs 12%; P = .017) were observed in natalizumab compared with other-DMT patients.

Improvements in organizing thoughts, a cognitive component of the assessment, was significantly higher for natalizumab patients versus other-DMT patients (24% vs 14%; P = .021). Associations of “feel-good” experiences such as increased physical, emotional, and cognitive functioning, which were more commonly observed in natalizumab patients, were consistent with qualitative interviews.

In previous studies, patients had self-reported a “feel-good” experience while receiving natalizumab treatment. This study aimed to confirm previous reports by comparing surveys results of “feel-good” experiences in adult patients with RRMS who were on either natalizumab or other DMTs . The surveys asked patients about their current DMT use and its “feel-good” effect assessed by self-reported improvements in physical, emotional, and cognitive domains.

Continue

::::::::::::::::::::::::::::::::::::::;;;;;;;;;;;;;;;;;;;;;:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::


Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews